India’s Sun Pharmaceutical Industries plans to raise around 100 billion rupees ($1.04 billion) through a rupee-denominated debt sale, according to three sources. The funds are expected to partly refinance a bridge loan taken to finance its acquisition of US healthcare company Organon & Co. Sun Pharma, India’s largest drugmaker by market value, secured a nearly […]Continue Reading
